Reuters -- Catalyst Pharmaceutical Partners Inc said it will continue to develop its lead drug candidate for the treatment of cocaine and methamphetamine addiction after it reviewed data from a mid-stage trial and a proof-of-concept study.
Reuters -- Catalyst Pharmaceutical Partners Inc said it will continue to develop its lead drug candidate for the treatment of cocaine and methamphetamine addiction after it reviewed data from a mid-stage trial and a proof-of-concept study.
